Dong-Hua Yang

List of Publications by Year
in descending order

62 papers	2,974 citations	201674 27 h-index	175258 52 g-index
66 all docs	66 docs citations	66 times ranked	4285 citing authors

#	Article	IF	Citations
1	Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin. European Journal of Medicinal Chemistry, 2022, 231, 114155.	5.5	3
2	BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion. Molecular Cancer, 2022, 21, 59.	19.2	21
3	A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Molecular Cancer, 2022, 21, 66.	19.2	18
4	Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resistance Updates, 2022, 61, 100822.	14.4	29
5	Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Molecular Cancer, 2022, 21, .	19.2	0
6	Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level. Journal of Pharmaceutical and Biomedical Analysis, 2021, 201, 114129.	2.8	18
7	Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Bosnian Journal of Basic Medical Sciences, 2021, , .	1.0	0
8	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Frontiers in Oncology, 2021, 11, 731260.	2.8	6
9	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Letters, 2020, 472, 132-141.	7.2	10
10	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. , 2020, 216, 107672.		52
11	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Frontiers in Pharmacology, 2020, 11, 1208.	3.5	23
12	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Frontiers in Cell and Developmental Biology, 2020, 8, 601400.	3.7	18
13	Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. Cancers, 2020, 12, 3249.	3.7	19
14	Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter. European Journal of Pharmacology, 2020, 881, 173185.	3.5	40
15	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. Frontiers in Oncology, 2020, 10, 228.	2.8	15
16	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2020, 10, 955.	2.8	31
17	Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2020, 63, 8157-8178.	6.4	25
18	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers, 2020, 12, 466.	3.7	37

#	Article	IF	Citations
19	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 1387.	4.1	25
20	Application of Immunohistochemistry in Basic and Clinical Studies. Methods in Molecular Biology, 2020, 2108, 43-55.	0.9	4
21	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Frontiers in Oncology, 2019, 9, 514.	2.8	29
22	WBâ€PBPKapproach in predicting zidovudine pharmacokinetics in preterm neonates. Biopharmaceutics and Drug Disposition, 2019, 40, 341-349.	1.9	5
23	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4095.	4.1	19
24	CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 125-149.		12
25	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2019, 9, 313.	2.8	28
26	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. Future Medicinal Chemistry, 2019, 11, 323-336.	2.3	31
27	Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2019, 25, 3430-3442.	7.0	51
28	Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Cellular Physiology and Biochemistry, 2018, 45, 1515-1528.	1.6	48
29	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters, 2018, 421, 186-198.	7.2	96
30	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. Frontiers in Pharmacology, 2018, 9, 1236.	3.5	41
31	Modulating ROS to overcome multidrug resistance in cancer. Drug Resistance Updates, 2018, 41, 1-25.	14.4	420
32	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochemical Pharmacology, 2018, 158, 274-285.	4.4	47
33	GSK1904529A, a Potent IGFâ€IR Inhibitor, Reverses MRP1â€Mediated Multidrug Resistance. Journal of Cellular Biochemistry, 2017, 118, 3260-3267.	2.6	21
34	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. Biochemical Pharmacology, 2017, 132, 29-37.	4.4	28
35	A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway. Journal of Medicinal Chemistry, 2017, 60, 1449-1468.	6.4	93
36	Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. Oncotarget, 2017, 8, 29760-29770.	1.8	31

#	Article	IF	Citations
37	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules, 2016, 21, 1236.	3.8	37
38	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resistance Updates, 2016, 27, 14-29.	14.4	511
39	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Scientific Reports, 2016, 6, 25694.	3.3	48
40	Musashi-2 (MSI2) supports TGF-Î² signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6955-6960.	7.1	120
41	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. Oncotarget, 2016, 7, 5877-5891.	1.8	28
42	Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. Cell Reports, 2015, 12, 1927-1938.	6.4	67
43	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical Pharmacology, 2014, 89, 52-61.	4.4	47
44	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	1.8	41
45	Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research, 2013, 19, 6633-6643.	7.0	29
46	Schwann Cell Myelination Requires Integration of Laminin Activities. Journal of Cell Science, 2012, 125, 4609-19.	2.0	49
47	Renal collecting system growth and function depend upon embryonic Î³1 laminin expression. Development (Cambridge), 2011, 138, 4535-4544.	2.5	27
48	câ€fos elimination compensates for disabledâ€2 requirement in mouse extraembryonic endoderm development. Developmental Dynamics, 2009, 238, 514-523.	1.8	10
49	Disabled-2 Is an Epithelial Surface Positioning Gene. Journal of Biological Chemistry, 2007, 282, 13114-13122.	3.4	68
50	Laminin matrix assembly and the mediation of epithelial differentiation. FASEB Journal, 2007, 21, A90.	0.5	0
51	Disabled-2 Heterozygous Mice Are Predisposed to Endometrial and Ovarian Tumorigenesis and Exhibit Sex-Biased Embryonic Lethality in a p53-Null Background. American Journal of Pathology, 2006, 169, 258-267.	3.8	28
52	Temporally regulated expression of Lin-28 in diverse tissues of the developing mouse. Gene Expression Patterns, 2003, 3, 719-726.	0.8	160
53	Disabled-2 Is Essential for Endodermal Cell Positioning and Structure Formation during Mouse Embryogenesis. Developmental Biology, 2002, 251, 27-44.	2.0	156
54	Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer, 2002, 94, 2380-2392.	4.1	71

#	Article	IF	Citations
55	The expression of gastric H+-K+-ATPase mRNA and protein in developing rat fundic gland. The Histochemical Journal, 2001, 33, 159-166.	0.6	5
56	Expression of N-acetylglucosamine residues in developing rat fundic gland cells. The Histochemical Journal, 2000, 32, 187-193.	0.6	5
57	Sulfated Glycosaminoglycans In Guinea Pig Neutrophils Studied by Use of Cationic Colloidal Gold. Journal of Histochemistry and Cytochemistry, 1999, 47, 881-887.	2.5	5
58	Phenotypic Immunostaining of Mucus-Secreting Cells of Foregut Origin.. Acta Histochemica Et Cytochemica, 1999, 32, 135-140.	1.6	3
59	Sulphated glycosaminoglycans in guinea pig eosinophils studied by means of cationic colloidal gold. The Histochemical Journal, 1998, 30, 687-692.	0.6	4
60	Sulfated glycosaminoglycans in guinea pig basophils studied by means of cationic colloidal gold. Histochemistry and Cell Biology, 1998, 109, 189-194.	1.7	3
61	Immunocytochemistry and in situ hybridization studies of pepsinogen C-producing cells in developing rat fundic glands. Cell and Tissue Research, 1998, 293, 121-131.	2.9	18
62	Ontogeny of sulphated glycoconjugate-producing cells in the rat fundic gland. The Histochemical Journal, 1996, 28, 33-43.	0.6	22